The country of origin of a CEFALY Enhanced Kit (SKU 10701)
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Key passages, quoted from the ruling
- As such, the country of origin of the CEFALY Enhanced (main device) will be Taiwan.
- Accordingly, the country of origin of the kit for duty purposes will be Taiwan.
Ruling text
In your letter dated August 11, 2025, you requested a country of origin ruling on a CEFALY Enhanced Kit (SKU 10701). Additional information was submitted via email dated August 20, 2025. The CEFALY Enhanced kit (SKU 10701) is intended for both the acute treatment and preventive therapy of migraines in adults. SKU 10701 is similar to SKU 10801, previously ruled on in NY Ruling N351106, dated July 31, 2025. However, SKU 10701 does not include Bluetooth connectivity.
The imported kit includes one main device (CEFALY Enhanced), a charging dock, three reusable adhesive electrodes, a resealable electrode bag, a USB charging cable, a plastic carrying case, user manuals, quick start guide, and packaging. The CEFALY Enhanced (main device) generates a treatment signal that is sent to stimulate and desensitize the trigeminal nerve. The user applies a reusable adhesive electrode to the forehead and attaches the main device magnetically.
Upon activation, the device delivers mild electrical pulses to the ophthalmic branch of the trigeminal nerve. The main device consists of a top cover, a button cover, a rubber button, a plastic switch, a main printed circuit board assembly (PCBA), a battery, a flex PCBA assembly, a conductive spring, two flex PCB mountings, two t-shape magnets, a conductive metal part, a EVA upper side, left side, and right side of battery, a back housing, and a device label. The electrodes are made in Taiwan.
The charging dock, cable, carrying case, and remaining items of the kit are made in China. The PCBAs of the main device are manufactured and programmed with firmware in Taiwan. This firmware, developed in Belgium, enables the therapeutic functionality of the device. It governs the main device operation, which is the defining purpose of the product. The firmware upload transforms the inert hardware into an operational medical device.
The PCBA production process in Taiwan includes: Mounting of electrical components onto the two sides of the main PCB and flex PCBs via Surface Mount Technology (SMT) Verifying component placement and solder quality on the populated boards using Automated Optical Inspection (AOI) system Integrating the main board and flex board into a single assembly Loading firmware into the memory of the main PCBA Testing Storing completed PCBAs pending shipment Production process in China: The PCBAs of the main device are transported to China, where they are assembled into the final housing.
This step includes connecting the PCBA to a rechargeable battery, integration with the mechanical button and enclosure, and final enclosure sealing and packaging. When determining the country of origin, the substantial transformation analysis is applicable. See, e.g., Headquarters Ruling Letter (“HQ”) H301619, dated November 6, 2018.
The test for determining whether a substantial transformation will occur is whether an article emerges from a process with a new name, character, or use different from that possessed by the article prior to processing. See Texas Instruments Inc. v. United States, 681 F.2d 778 (C.C.P.A. 1982). This determination is based on the totality of the evidence. See National Hand Tool Corp. v.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N352290).